|Bid||12.45 x 900|
|Ask||15.95 x 1000|
|Day's Range||13.06 - 13.59|
|52 Week Range||7.84 - 19.95|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.17|
Five Prime Therapeutics Inc NASDAQ/NGS:FPRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NeutralShort interest is moderate for FPRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 15. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding FPRX are favorable, with net inflows of $2.60 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Five Prime (FPRX) recently held a quarterly conference call and, importantly, all of the company's timelines remain on track; it has developed a broad pipeline with five drug candidates now in human clinical development, observes John McCamant, biotech expert and editor of The Medical Technology Stock Letter.
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Wednesday, March 13, 2019 at 8:40am ET.
SOUTH SAN FRANCISCO, Calif.-- -- Significant Pipeline Expansion and Strong Clinical Execution in 2018 Phase 3 FIGHT Registrational Trial in Gastric and GEJ Cancer Enrolling Phase 2 Cabiralizumab/ Opdivo ® Trial in Pancreatic Cancer Enrolling Phase 1 Starts for FPA150, FPT155 and BMS-986258 Multiple Data Readouts in 2019 Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused ...
SOUTH SAN FRANCISCO, Calif.-- -- First-in-class antibody targeting B7-H4 Dual mechanism blocks a T cell checkpoint pathway and delivers potent antibody-dependent cell-mediated cytotoxicity against tumor cells that express B7-H4 B7-H4 is over-expressed on hard-to-treat solid tumors with low response to checkpoint inhibition Phase 1b trial will test monotherapy FPA150 in patients with breast, ovarian, ...
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019, after the U.S. financial markets close.
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019 at 2:00 pm PT.
Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that a poster entitled “Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Cancer” was presented today at the ASCO Gastrointestinal Cancer Symposium in San Francisco. The poster (Board J1, Abstract #91) can be found online at Five Prime Therapeutics Scientific Publications. “Gastric cancer with FGFR2b overexpression or FGFR2 gene amplification is associated with a poor prognosis for patients with advanced disease,” said Helen Collins, M.D., senior vice president and chief medical officer of Five Prime.
NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The 17-year-old biotech company, a big player in antibody drug research and development, will focus its cash on a maturing pipeline of experimental drugs while letting go of some longtime employees.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today a corporate restructuring to focus resources on its development pipeline, comprising five clinical-stage cancer programs in various solid tumor types and addressing multiple cell types in the tumor microenvironment. “While we are on track for multiple data read-outs and potential phase advances from our pipeline in 2019, the Executive Team and Board felt it was necessary to sharpen our focus on our current clinical programs and the advancement of our later-stage research initiatives,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.
– Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric and Gastric Esophageal Junction Cancer –
M&A momentum is building in the pharma space, with more deals announced last week, including Eli Lilly And Co (NYSE: LLY )'s $8-billion move to acquire Loxo Oncology Inc (NASDAQ: LOXO ). The following ...